Bosutinib Dosing Guidelines

Bosutinib is a targeted therapy drug used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) and belongs to the tyrosine kinase inhibitor (TKI) class of drugs. Bosutinib treats chronic myelogenous leukemia by targeting the BCR-ABL protein and inhibiting the proliferation of leukemia cells. The method of taking bosutinib is relatively simple, but in order to ensure its efficacy and reduce side effects, patients need to follow certain guidelines during its administration.

For adult patients with newly diagnosed chronic phase diseaseThe recommended dose of bosutinib is 400 mg orally once daily. It should be noted that bosutinib should be taken with food, which can help reduce adverse drug reactions and improve drug absorption efficiency. Patients should insist on taking medication every day according to the doctor's guidance and avoid missing doses or increasing or decreasing the dose at will to ensure the maximum treatment effect.

For adult patients with Ph+ CML who are in the chronic phase, accelerated phase or blast phase and have developed resistance or intolerance to previous treatmentsThe recommended dose is 500 mg once daily, also required to be taken with food. This dose is relatively high, because these patients have more complex conditions and are resistant to previous treatments, and higher doses of bosutinib can better control the disease.

When treating pediatric patients, dosage is usually adjusted based on body surface area. For newly diagnosed pediatric patients with chronic phasePh+ CML, the recommended dose is 300 mg/m² once a day with food. For those pediatric patients who have developed resistance or intolerance to previous treatment, the recommended dose is 400mg/m², once a day, and also needs to be taken with food. Dosage adjustments in pediatric patients are important because children may metabolize drugs differently than adults, requiring dose adjustments based on body surface area to ensure safety and efficacy.

Reference materials:https://go.drugbank.com/drugs/DB06616